TG-1801 (also known as NI-1701, TG Therapeutics, Inc.)is a 1:1 IgG1 bispecific κλ antibody (CD19 × CD47) that combines malignant B cell targeting and selective CD47 blockade.171,172 Accordingly, TG-1801 specifically targeted double-positive tumor cells and showed antitumor efficacy through ADCP in vitro and in vivo.171 A phase I clinical trial for evaluating the safety and optimal dosage of TG-1801 (NCT03804996) is ongoing. This evidence concerns the gene CD19 and neoplasm.